It’s not surprising there’s a considerable amount of attention being paid to the five different vaccines in late-stage development for COVID-19. Every phase completed is a little victory in a time where wins are few. So when one of the vaccines furthest along, the one being produced in concert by AstraZeneca and Oxford University, had to halt its trials because of a severe adverse effect experienced by one of its U.K. participants, it makes news. 

But that isn’t dire news, according to several life sciences attorneys with experience in the stop-and-go process of biological product development. 

Brian Malkin